Initial commercial application, Prostate Px®+, provides a personalized prediction of
prostate cancer progression at time of diagnosis
YONKERS, N.Y., Dec. 16,
2008-Aureon Laboratories, Inc., a specialized laboratory dedicated to
advancing personalized cancer treatment through predictive pathology, today announced
that the United States Patent and Trademark Office issued patent numbers 7,461,048
and 7,467,119, which cover the company’s systems and methods for evaluating the
occurrence of any medical condition in a patient where clinical, imaging
and molecular data are combined and appraised. This approach, known as “Systems Pathology,” combines several enhanced
technologies - image analysis and biomarker evaluation - with clinical data and
advanced mathematics to produce
a predictive score indicating the likelihood of disease progression.
The initial application of Aureon’s Systems Pathology
platform is Prostate Px®+, a laboratory developed test which provides a personalized
prediction of prostate cancer progression at the time of diagnosis. 85% of
patients diagnosed with the disease are initially considered low or intermediate
risk. Of great clinical value, Prostate Px+ helps identify those patients
within this large group that are actually at high risk for progression, thus allowing
for timely insight prior to a treatment decision. Prostate Px+ also
identifies those patients with favorable pathology who may have a more indolent
course of disease.
“These patents further protect our intellectual property
position and establish the company as a leader in personalized prognostics,”
said Dr. Vijay Aggarwal, chief executive officer of Aureon Laboratories. “We
also believe these patents have wide applicability in the analysis of many
other solid tumors.”
About Aureon Laboratories
Aureon Laboratories' mission is to enable personalized
patient care through predictive pathology. Aureon has developed a high
throughput systems pathology technology platform to predict individual clinical
outcomes through the interrogation of tissue. The platform generates and
analyzes an integrated, digital view of clinical findings, tissue micro-anatomy
and tissue molecular pathology to determine which combination of features
predicts specified individual clinical outcomes. Allied with major cancer
centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that
provides predictive pathology services to the practicing physician. For more
information about Aureon, go to www.aureon.com
or call 1-888-SYS-PATH.